TCF2 Methylation in Ovarian Cancer
Author Information
Author(s): K Terasawa, M Toyota, S Sagae, K Ogi, H Suzuki, T Sonoda, K Akino, R Maruyama, N Nishikawa, K Imai, Y Shinomura, T Saito, T Tokino
Primary Institution: Sapporo Medical University
Hypothesis
Is TCF2 a target for epigenetic inactivation in ovarian cancer?
Conclusion
TCF2 is involved in the development of ovarian cancers and may represent a useful target for their detection and treatment.
Supporting Evidence
- TCF2 was methylated in 53% of ovarian cancer cell lines.
- Restoration of TCF2 expression was achieved using a methyltransferase inhibitor.
- TCF2 methylation was not detected in normal ovarian tissues.
Takeaway
Scientists found that a gene called TCF2 is often turned off in ovarian cancer, which might help doctors find and treat this disease better.
Methodology
The study used methylation screening techniques and analyzed TCF2 expression in ovarian cancer cell lines and primary cancers.
Limitations
The study did not explore the specific mechanisms of TCF2 methylation in different tumor types.
Participant Demographics
The study included ovarian cancer specimens from patients at Sapporo Medical University Hospital.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website